Clinical trial
A Phase 2b, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis
NCT07904754 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Moderately to Severely Active Rheumatoid Arthritis
- Lead sponsor
- AbbVie
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- December 7, 2026
- Completion date
- July 31, 2029
- Enrollment
- 250 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
rheumatoid arthritis
Arms
As registered; 5 arms.
-
ABBV-2294 Dose A
Participants will receive co-administration of ABBV-722 and upadacitinib
-
ABBV-2294 Dose B
Participants will receive co-administration of ABBV-722 and upadacitinib
-
ABBV-2294 Dose C
Participants will receive co-administration of ABBV-722 and upadacitinib
-
ABBV-722 Monotherapy
Participants will receive ABBV-722. At Week 12, participants will then be blindly switched to co-administration of ABBV-722 and upadacitinib.
-
Upadacitinib Monotherapy
Participants will receive upadacitinib.
Primary endpoints
Registered primary outcome measures; 2 primary.
-
Percentage of Participants Achieving ACR50 Response
The ACR50 response is defined as at least 50% improvement in the American College of Rheumatology (ACR) criteria for rheumatoid arthritis. The ACR50 response requires at least 50% improvement in tender and swollen joint counts and at least 50% improvement in at least 3 of the following 5 measures: patient's assessment of pain, patient's global assessment of disease activity, physician's global assessment of disease activity, patient's assessment of physical function (HAQ-DI), and acute phase reactant (CRP or ESR).
-
Number of Participants Experiencing Adverse Events
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Lead sponsor's other trials
AbbVie, most recent start first.
+1,194 more trials See the organization page
Similar trials
Same condition (Arthritis, Rheumatoid) and phase, most recent start first.
+451 more trials See the condition page